Codexis decodes cost

Biocatalyst play Codexis Inc. also was on the road and hopes to do its IPO this week.

The company uses synthetic enzymes to improve manufacturing for biopharmaceutical companies and biofuels. Last year, it posted $82.9 million in revenue, 76% of which came from a partnership with Royal Dutch Shell (NYSE:RDS-B). It had a 2009 operating loss of $18.4 million and $55.6 million in cash at Dec. 31...